New investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing promising results in managing excess mass and related second-type disease. Animal data suggest a novel action contributing https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/